CD155-targeted CAR-T cells, therefore, may represent a potential approach for treating a wide range of cancers, including both AML and solid tumors, potentially expanding the scope of and reducing costs of effective cellular immunotherapy of cancer. Here, PVR is linked to acute myeloid leukemia.